-
Highlights sneak peek! The Chinese expert consensus on the diagnosis and treatment of dermatomyositis has been released
Time of Update: 2023-01-06
Recently, the "Chinese Expert Consensus on the Diagnosis and Treatment of Dermatomyositis in Adults" was officially published online in the Chinese Journal of Dermatology, answering these key clinical questions.
-
Highlights sneak peek! The Chinese expert consensus on the diagnosis and treatment of dermatomyositis has been released
Time of Update: 2023-01-06
Recently, the "Chinese Expert Consensus on the Diagnosis and Treatment of Dermatomyositis in Adults" was officially published online in the Chinese Journal of Dermatology, answering these key clinical questions.
-
Guarding the Brain: A Special Immune System That Protects the Brain's Gray Matter Nature's long article
Time of Update: 2023-01-01
”Since those early experiments, Schwartz's team and others have amassed a wealth of evidence that immune cells do play an important role in the brain, even without autoimmune diseases.
-
Jiachen Xihai broad-spectrum mRNA novel coronavirus seedlings were approved for phase I/II registration clinical trial by the US Food and Drug Administration
Time of Update: 2023-01-01
On November 19, 2022, Jiachen Xihai Biotechnology Co. , Ltd. (hereinafter referred to as "Jiachen Xihai"), a fast-growing innovative drug R&D biotechnology company, announced that its self-developed
-
In Alzheimer's disease clinical trials, can changes in Aβ levels represent cognitive changes
Time of Update: 2022-11-01
gov identified RCT-related drugs that were 'completed', 'terminated', or 'effective, not recruited'; In addition, the trial required a placebo-controlled group and standardized uptake ratio (SUVR) for amyloid β measured by positron emission tomography (PET) and cognitive function measured by the Dementia Severity Rating Scale (CDR-SB), Alzheimer's Disease Rating Scale-Cognitive Scale (ADAS-Cog), and the Simple Mental State Scale (MMSE) to verify the relationship between changes in Aβ-PET SUVR and changes in cognitive function.
-
Ascentage Pharma submitted an IND application for the treatment of systemic lupus erythematosus with the Bcl-2 inhibitor APG-2575, which will open up the exploration of non-oncology fields
Time of Update: 2022-10-31
Ascentage Pharma (6855. HK) announced on October 26 that it has officially submitted a new drug clinical trial (IND) application to the Center for Drug Evaluation (CDE) of the National Medical Produc
-
The boon for patients with acromegaly – Lanreotide Autogel can benefit patients with limb megaly
Time of Update: 2022-10-21
Lanreotide acetate sustained-release injection (prefilled) (Lanreotide ATG) is one of the main SSAs that have been marketed in China, and is the only drug approved in the world for extended dosing interval therapy in patients with large limbs, today we will deeply analyze the short-term and long-term efficacy, safety, impact on quality of life (QoL) and related factors that can predict long-term efficacy of lanreotide ATG treatment, in order to provide more treatment references for clinical practice.
-
Menarini Group's drug elastrant has been granted priority review status by the FDA
Time of Update: 2022-08-20
About the Phase 3 study of elasitran (RAD1901) and EMERALD Elastrant is an investigational selective estrogen receptor degrader (SERD) currently being evaluated as a once-daily oral treatment for patients with ER+/HER2- advanced or metastatic breast cancer .
-
Another domestic rare disease drug for children is about to be approved for marketing
Time of Update: 2022-08-10
At present, only imported products have been approved, and the domestic pharmaceutical company Zhongyuandong Bio is the exclusive application for generic listing vigabatrin powder is a highly effective drug for the treatment of infantile spasms.
-
The purchase of basic infusion tapes in Heilongjiang Province has started
Time of Update: 2022-05-01
The applicant enterprise must meet the following conditions: (1) Listed drugs that fall within the scope of the catalogue of purchased varieties and have obtained a valid domestic registration approval document .
-
Changes to drug prices after DRG implementation
Time of Update: 2022-03-09
Chart: Generic Drug Substitution Ratio of Various Types of Institutions in Japan in 2020Data source: Japanese Ministry of Health, Labour and Welfare, Latitude Health analysisIf we look at various regions, the regions with a high substitution rate of DPC inpatient generic drugs have a correspondingly higher substitution rate of outpatient and prescription retail, which means that the medication habits of the entire region have changed significantly at the same time .
-
Qilu Pharmaceutical sprints domestic nintedanib, the second nintedanib sales exceed 600
Time of Update: 2022-03-06
Sales of nintedanib ethanesulfonate soft capsules in Chinese urban physical pharmacies in recent years (unit: ten thousand yuan) Source: Minet.
Sales of nintedanib ethanesulfonate soft capsules in Chinese urban physical pharmacies in recent years (unit: ten thousand yuan) Source: Minet.
-
Aims to functionally cure hepatitis B RNAi immune combination therapy to carry out phase 2 clinical trials
Time of Update: 2022-01-11
Reference materials:[1] Vir Biotechnology Announces Initiation of Phase 2 Clinical Trial Evaluating VIR-2218, Selgantolimod and Nivolumab for the Treatment of Chronic Hepatitis B Virus Infection.
December 9, 2021, from https:// 2021/12/09/2349250/0/en/Vir-Biotechnology-Announces-Initiation-of-Phase-2-Clinical-Trial-Evaluating-VIR-2218-Selgantolimod-and-Nivolumab-for-the-Treatment-of- Chronic-Hepatitis-B-Virus-Infection.
-
The results of the national talks are released. The full analysis of key products involves Hengrui, Rongchang, and Geli Pharmaceuticals, etc
Time of Update: 2021-12-24
, Fluzoparil Capsules, Hetropopaethanolamine Tablets, and Azilsartan Tablets; Two new drugs are included in the 2021 medical insurance list by Golly Pharmaceuticals and Rongchang Biologics, namely danorevir sodium tablets and ravi hydrochloride Davir tablets, vedicitumumab for injection, and taltacept for injection .
-
Tens of billions of antithrombotic drugs have fallen into the "Altar"! TOP10 ranking changes
Time of Update: 2021-12-05
According to data from Meinenet, the market for terminal antithrombotic drugs in public medical institutions in China in 2021H1 increased by 13.
Ticagrelor tablets ranked sixth in the TOP10 terminal antithrombotic drug products of China's public medical institutions in 2020, and fell out of the top ten in 2021H1 .
